CO6400019A1 - Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion - Google Patents

Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion

Info

Publication number
CO6400019A1
CO6400019A1 CO10110534A CO10110534A CO6400019A1 CO 6400019 A1 CO6400019 A1 CO 6400019A1 CO 10110534 A CO10110534 A CO 10110534A CO 10110534 A CO10110534 A CO 10110534A CO 6400019 A1 CO6400019 A1 CO 6400019A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
mitochondrial
pharmaceutically acceptable
effective amount
therapeutically effective
Prior art date
Application number
CO10110534A
Other languages
English (en)
Inventor
Costa Pereira Jose Roberto Da
Marcio Falci
Alario Mauricio Matteis
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of CO6400019A1 publication Critical patent/CO6400019A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende: (a) una cantidad terapéuticamente eficaz de por lo menos un compuesto de la clase de racetam o su sal farmacéuticamente aceptable o sus isómeros; (b) una cantidad terapéuticamente eficaz de carnitina o su sal farmacéuticamente aceptable o sus isómeros y (c) un vehículo farmacéuticamente aceptable. La composición de la invención puede, en forma adicional contener Coenzima Q10, pudiendo, en forma opcional, contener una cantidad terapéuticamente eficaz de por lo menos un agente terapéutico asociado con trastorno mitocondrial y/o metabólico. Preferentemente, el agente terapéutico asociado con trastorno mitocondrial y/o metabólico es seleccionado entre un agente hipocolesterolémico del grupo de las estatinas, agente hipoglucémico y agente antiepiléptico.La invención también incluye un método de tratamiento de trastornos mitocondriales que comprende la administración de la composición farmacéutica de la invención; el uso de la composición farmacéutica de la invención en la preparación de un medicamento para el tratamiento y/o prevención de trastornos mitocondriales en un mamífero y un proceso de preparación de la composición farmacéutica de la invención.
CO10110534A 2008-02-29 2010-09-07 Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion CO6400019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800432 2008-02-29

Publications (1)

Publication Number Publication Date
CO6400019A1 true CO6400019A1 (es) 2012-03-15

Family

ID=41016503

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10110534A CO6400019A1 (es) 2008-02-29 2010-09-07 Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion

Country Status (20)

Country Link
US (1) US20110052556A1 (es)
EP (1) EP2262495B1 (es)
JP (1) JP5677856B2 (es)
KR (1) KR101686917B1 (es)
CN (1) CN102014896A (es)
AR (1) AR070713A1 (es)
AU (1) AU2009219050B2 (es)
CA (1) CA2716020C (es)
CL (1) CL2009000478A1 (es)
CO (1) CO6400019A1 (es)
ES (1) ES2699458T3 (es)
HU (1) HUE042168T2 (es)
IL (1) IL207852A (es)
MX (1) MX2010009290A (es)
PE (1) PE20091564A1 (es)
PL (1) PL2262495T3 (es)
PT (1) PT2262495T (es)
TR (1) TR201820411T4 (es)
WO (1) WO2009105853A2 (es)
ZA (1) ZA201006031B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525899B (zh) * 2012-01-17 2013-04-17 山东罗欣药业股份有限公司 一种奥拉西坦组合物注射液及其制备方法
CN103099211A (zh) * 2012-12-21 2013-05-15 洪万雄 一种融合辅酶q10的广谱性一氧化氮保健品
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
CN108853029A (zh) * 2018-09-07 2018-11-23 南通雅本化学有限公司 一种罗苏伐他汀的制备方法
WO2022231257A1 (ko) * 2021-04-26 2022-11-03 주식회사 케이에스비튜젠 옥시라세탐을 포함하는 근육질환 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1293067B1 (it) 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
CA2375378C (en) * 1999-06-08 2009-08-11 Arduino Arduini Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
RU2266736C2 (ru) 2000-05-09 2005-12-27 Канека Корпорейшн Способ и композиции для ингибирования артериосклероза
US20020058026A1 (en) * 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
BRPI0410235A (pt) * 2003-04-16 2006-05-09 Memory Pharm Corp inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006110588A2 (en) * 2005-04-11 2006-10-19 The Trustees Of Columbia University In The City Of New York Methods for treating mild cognitive impairment
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress

Also Published As

Publication number Publication date
WO2009105853A8 (en) 2010-02-18
CA2716020C (en) 2018-10-16
KR20100126454A (ko) 2010-12-01
EP2262495A4 (en) 2012-01-11
AU2009219050A1 (en) 2009-09-03
WO2009105853A2 (en) 2009-09-03
KR101686917B1 (ko) 2016-12-15
TR201820411T4 (tr) 2019-01-21
AU2009219050B2 (en) 2014-04-24
PT2262495T (pt) 2019-02-04
US20110052556A1 (en) 2011-03-03
PL2262495T3 (pl) 2019-03-29
WO2009105853A3 (en) 2009-11-26
HUE042168T2 (hu) 2019-06-28
JP5677856B2 (ja) 2015-02-25
PE20091564A1 (es) 2009-11-04
MX2010009290A (es) 2010-09-14
ES2699458T3 (es) 2019-02-11
IL207852A0 (en) 2010-12-30
CA2716020A1 (en) 2009-09-03
JP2011513246A (ja) 2011-04-28
IL207852A (en) 2015-07-30
EP2262495B1 (en) 2018-10-31
ZA201006031B (en) 2012-01-25
EP2262495A2 (en) 2010-12-22
AR070713A1 (es) 2010-04-28
CL2009000478A1 (es) 2009-08-07
CN102014896A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR091089A1 (es) Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
CO6400019A1 (es) Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
UY31826A (es) Compuesto peptídico y su uso

Legal Events

Date Code Title Description
FC Application refused